CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC

January 21, 2017

This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.

The CHARTA trial tested FOLFOX plus bevacizumab with or without irinotecan in patients with metastatic colorectal cancer.

In this video, Hans-Joachim Schmoll, MD, PhD, of the Martin Luther University Halle-Wittenberg in Halle, Germany, discusses results of the trial, covering the survival outcomes, subgroup analyses, and quality-of-life data.

The results of CHARTA (abstract 658) were presented at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.